Dr Srividya N

About Doctor :

Expertise :

• Chemotherapy
• Targeted therapy Immunotherapy
• Colon & GI Cancer
• Kidney & GU Cancer
• Breast Cancer Treatment
• Lung cancer
• Leukemia
• Lymphoma
• Myeloma
• Pediatric oncology
• Cancer Screening
• Ovary Cancer
• Bone Cancer
• Thyroid Cancer Palliative treatment Transplant

Past Experience :

• 2012-2015 - Senior Resident at Nims, Hyderabad
• 2015-2016 - Senior Resident at Ggh, Guntur
• 2015-2018 - Consultant Medical Oncologist at City Cancer Center, Vijayawada
• 2018- March 2021 - Consultant Medical Oncologist at Hcg, Vijayawada
• April 2021 -till Date - Consultant Medical Oncologist Medicover Cancer Institute, Nellore

Publications :

• Response to Imatinib Mesylate in Childhood Chronic Myeloid Leukemia in Chronic Phase”, South Asian J Cancer 2014 Oct;3(4):203-5.  
• Impact of Imatinib compliance on the cytogenetic response at six months in pediatric CML CP. Indian Journal of Pediatrics 2016 Feb 3. DOI 10.1007/s12098-015-2007-9.
• Impact of treatment protocol on outcome of localized Ewing’s sarcoma. South Asian J Cancer 2016;5:194-5  
• Trends in management of acute lymphoblastic leukemia: Influence of Insurance based healthcare and treatment compliance on the outcome of adolescents and aduls with acute lymphoblastic leukemia. Indian J Med Paediatr Oncol 2016 Jan-Mar; 37 (1):32-7  
• Cytogenetic and Molecular response among EUTOS risk groups in children with CML CP on Imatinib treatment. Egypt J Haematol 2017;42:74-7.
• Effectiveness of three prognostic scoring systems in predicting the response and outcome in pediatric CML CP on frontline Imatinib. Indian J Med Paediatr Oncol 2017;38:282-6.Imatinib dose hike in suboptimal response and failure in CML CP: Results from a developing nation. journal of Clinical oncology 31,2013_suppl e18003   
• Cytogenetic and molecular response rates in AYA CML CP patients on imatinib based on the baseline BMI”, Annals of Oncology, Volume 27, Issue suppl_9, December 2016, mdw586.009,
• Safety and efficacy of Carboplatin, Capecitabine plus Cetuximab biweekly regimen in the first-line treatment of patients with recurrent/metastatic head and neck cancer (R/MSCCHN): Single center, retrospective study. Annals of Oncology, Volume 29, Issue suppl_9, November 2018, mdy438.029.
• Prognostic significance of NLR kinetics in operable triple negative breast cancer. e14201 journal of Clinical oncology 37,2019, no.15_suppl.

Memberships :

• American Society of Clinical Oncology
• European Society of Medical Oncology
• Indian Society of Immuno-oncology

Languages :

• English
• తెలుగు
• हिन्दी
• ಕನ್ನಡ